What ARA-290 / Cibinetide is
Cibinetide is an erythropoietin-derived peptide designed to target tissue-protective signaling without the classic erythropoietic effect.
ARA-290 / Cibinetide is grouped under Fitness + Recovery / Longevity + Skin / Approved / Clinical on PeptideFactCheck because it attracts interest because it sounds like a repair and inflammation peptide with a cleaner mechanism story than many underground products.
The useful starting point is to separate the molecule itself from the internet story around it. It attracts interest because it sounds like a repair and inflammation peptide with a cleaner mechanism story than many underground products.
Why people keep looking it up
It attracts interest because it sounds like a repair and inflammation peptide with a cleaner mechanism story than many underground products.
Cibinetide is an erythropoietin-derived peptide designed to target tissue-protective signaling without the classic erythropoietic effect.
ARA-290 / Cibinetide tends to stay in the conversation because it touches a familiar public theme: innate repair receptor, tissue protection, and neuropathy research. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Clinical-stage peptide with meaningful human work, but still far narrower than online marketing language.
There is human clinical work in specific disease contexts, but that does not automatically validate broad recovery or performance claims.
Preclinical literature explores tissue protection, inflammation, and neuropathy-related mechanisms.
Why this page carries the current tier: Clinical-stage peptide with meaningful human work, but still far narrower than online marketing language.
The current seed trail for ARA-290 / Cibinetide is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Disease-context research should not be casually generalized to athletic recovery or everyday optimization.
This remains investigational rather than FDA-approved in the contexts tracked here.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for ARA-290 / Cibinetide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for ARA-290 / Cibinetide is CID 91810664. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 91810664
- Formula
- C51H84N16O21
- Molecular weight
- 1257.3
- InChIKey
- WZTIQQBMSJTRBR-WYKNNRPVSA-N
Matched synonyms include Cibinetide, 1208243-50-8, ARA290, PHBSP, PH-BSP, ARA-290, ARA 290, pHBSP peptide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for ARA-290 / Cibinetide returns 4 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for ARA-290 / Cibinetide returns 60 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.